Alexander Egeberg1, Peter R Hansen2, Gunnar H Gislason3, Jacob P Thyssen4. 1. Department of Dermatology and Allergy, Herlev and Gentofte University Hospital, University of Copenhagen, Hellerup, Denmark; Department of Cardiology, Herlev and Gentofte University Hospital, University of Copenhagen, Hellerup, Denmark. Electronic address: alexander.egeberg@gmail.com. 2. Department of Cardiology, Herlev and Gentofte University Hospital, University of Copenhagen, Hellerup, Denmark. 3. Department of Cardiology, Herlev and Gentofte University Hospital, University of Copenhagen, Hellerup, Denmark; Danish Heart Foundation, Copenhagen, Denmark; National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark. 4. Department of Dermatology and Allergy, Herlev and Gentofte University Hospital, University of Copenhagen, Hellerup, Denmark.
Abstract
BACKGROUND: Recent studies have shown a higher prevalence of cardiovascular (CV) risk factors in patients with rosacea. However, it remains unknown whether rosacea represents an independent CV risk factor. OBJECTIVE: We evaluated the risk of myocardial infarction, stroke, CV death, major adverse CV events, and all-cause mortality, respectively. METHODS: Between January 1, 1997, and December 31, 2012, a total of 4948 patients with rosacea were identified and matched with 23,823 control subjects. We used Poisson regression to calculate incidence rate ratios. RESULTS: Adjusted incidence rate ratios were 0.75 (95% confidence intervals [CI] 0.57-1.00) for myocardial infarction, 1.08 (95% CI 0.86-1.35) for ischemic stroke, 1.01 (95% CI 0.61-1.67) for hemorrhagic stroke, 0.99 (95% CI 0.80-1.24) for CV death, 0.99 (95% CI 0.86-1.15) for major adverse CV events, and 0.95 (95% CI 0.85-1.06) for all-cause mortality. LIMITATIONS: We were unable to distinguish between the different subtypes and severities of rosacea. CONCLUSIONS: In this population-based study, rosacea was not associated with increased risk of adverse CV outcomes or death.
BACKGROUND: Recent studies have shown a higher prevalence of cardiovascular (CV) risk factors in patients with rosacea. However, it remains unknown whether rosacea represents an independent CV risk factor. OBJECTIVE: We evaluated the risk of myocardial infarction, stroke, CV death, major adverse CV events, and all-cause mortality, respectively. METHODS: Between January 1, 1997, and December 31, 2012, a total of 4948 patients with rosacea were identified and matched with 23,823 control subjects. We used Poisson regression to calculate incidence rate ratios. RESULTS: Adjusted incidence rate ratios were 0.75 (95% confidence intervals [CI] 0.57-1.00) for myocardial infarction, 1.08 (95% CI 0.86-1.35) for ischemic stroke, 1.01 (95% CI 0.61-1.67) for hemorrhagic stroke, 0.99 (95% CI 0.80-1.24) for CV death, 0.99 (95% CI 0.86-1.15) for major adverse CV events, and 0.95 (95% CI 0.85-1.06) for all-cause mortality. LIMITATIONS: We were unable to distinguish between the different subtypes and severities of rosacea. CONCLUSIONS: In this population-based study, rosacea was not associated with increased risk of adverse CV outcomes or death.
Authors: Bo Young Chung; Hye One Kim; Chun Wook Park; Na Gyeong Yang; Jae Yun Kim; Yun Su Eun; Euy Hyun Chung; Sung Yul Lee; Young Lip Park; Sang Hoon Lee; Nam Hun Heo; Min Jeong Shin; Jung Eun Kim Journal: Biomed Res Int Date: 2022-07-04 Impact factor: 3.246
Authors: Marcelle Silva-Abreu; Lupe Carolina Espinoza; María José Rodríguez-Lagunas; María-José Fábrega; Marta Espina; María Luisa García; Ana Cristina Calpena Journal: Int J Mol Sci Date: 2017-11-28 Impact factor: 5.923